SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-012415
Filing Date
2023-04-21
Accepted
2023-04-21 16:04:18
Documents
12
Period of Report
2023-04-20
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20230420.htm   iXBRL 8-K 31499
  Complete submission text file 0001628280-23-012415.txt   164611

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230420.xsd EX-101.SCH 1967
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230420_lab.xml EX-101.LAB 24181
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230420_pre.xml EX-101.PRE 12574
6 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230420_htm.xml XML 10023
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 23836308
SIC: 2834 Pharmaceutical Preparations